The purpose of the study was to evaluate in patients with recurrent intermediate-grade NHL, the tolerance to and efficacy of an intensive salvage regimen consisting of high doses of ifosfamide, etoposide and mitoxantrone with G-CSF support, followed by autologous stem cell transplantation and to identify prognostic fac- the 44 patients proceeded to autologous stem cell transplantation and one transplant-related death occurred. With a median follow-up of 52 months, progression-free survival at 2 years is 38% ± 14% and survival is 52% ± 15%. Data from these 44 patients were pooled with data on 53 patients who had received salvage treatment with MINE-ESHAP, for a multivariate analysis of prognostic factors. In multivariate analysis, serum LDH was strongly associated with survival. The use of a more intensive salvage regimen, did not result in a significant increase in long-term outcome, despite a high response rate. In conclusion, duration of treatment, response rates, treatment-related mortality and survival compare favorably with previous salvage regimens, but recurrence remains a major problem. Long-term survival in recurrent large cell lymphoma is influenced more by disease characteristics than by the type of salvage regimen used. Bone Marrow Transplantation (2001) 27, 397-404. Keywords: lymphoma; transplantation; prognostic factors Commonly used regimens for reinduction of patients with recurrent aggressive non-Hodgkin's lymphoma (NHL) are either platinum-based (DHAP or ESAP), 1 or ifosfamidebased (most commonly MINE).
Commonly used regimens for reinduction of patients with recurrent aggressive non-Hodgkin's lymphoma (NHL) are either platinum-based (DHAP or ESAP), 1 or ifosfamidebased (most commonly MINE). 2 Both types of regimens induce responses in approximately two thirds of patients and complete remission rates of approximately 30% to 40%. 3 Autologous transplantation results in durable remissions in approximately half of the responding patients, 3 but lack of response to pre-transplant chemotherapy and recurrence after transplantation limit the clinical impact of this strategy. Overall only approximately 20% of patients with recurrent NHL targeted for auto-transplant, achieve durable remissions. 4 Dose-intensity can be optimized by increasing the dose of a particular drug, or by decreasing the treatment interval (ie increasing the dose density). 5 We studied a salvage regimen consisting of high doses of ifosfamide, etoposide alternating with high-dose ifosfamide and mitoxantrone. With G-CSF support and prophylactic antibiotics, we were able to administer repeated doses of this regimen on a 3-to 4-week schedule, achieving a dose-intensity that was higher than previously possible with the MINE regimen. Here we present the long-term outcome of patients treated by this regimen. Furthermore, we compared the outcome of patients treated on this phase II study with that of patients treated between 1990 and 1994 on a phase II protocol with MINE/ESHAP 2 followed by autologous bone marrow transplantation with BEAC conditioning. 6 The combined data from these two studies allow us to identify disease, patient and treatment-related variables that determine the survival for patients with recurrent NHL.
Materials and methods
Patients between the ages of 16 and 61 years with recurrent aggressive lymphoma or with transformation from more indolent histology were eligible for this study (DM94-002) which accrued between 1994 and 1996. Histological documentation at the time of relapse by biopsy or fine needle aspiration cytology was done whenever feasible. All patients had initially been treated with an anthracyclinecontaining regimen and had achieved a complete response or a stable partial response. They had developed disease progression or recurrence after a treatment-free interval of at least 3 months. Patients who developed disease progression during their initial treatment (primary refractory) were not eligible. Patients with active CNS disease were not eligible and neither were those who were seropositive for HIV, HBV and HCV.
All patients underwent complete restaging including CT scan of the chest, abdomen and pelvis as well as unilateral bone marrow aspiration and biopsy. Patients also underwent pulmonary function testing and cardiac radionuclide scan or ultrasound. Those with significant abnormalities (diffusion capacity, functional vital capacity or FEV 1 less than 50% of predicted or left ventricular ejection fraction less than 45%) were not eligible. Similarly, patients with serum creatinine Ͼ1.7 mg%, bilirubin Ͼ2 mg%, granulocytes Ͻ1.5 × 10 9 /l or platelets Ͻ100 × 10 9 /l (unless due to bone marrow involvement) were not eligible.
Chemotherapy (Figure 1)
Induction consisted of a cycle of ifosfamide and etoposide with growth factor support. Stem cell apheresis was performed upon recovery from the first treatment cycle. Patients underwent restaging after every cycle. Those achieving CR were consolidated with high-dose BEAM with stem cell support. Patients achieving partial remission or stable disease after ifosfamide/etoposide received a cycle of ifosfamide and mitoxantrone.
Patients achieving CR after ifosfamide and mitoxantrone were consolidated with high-dose BEAM and stem cell support. Those achieving partial remission or stable disease were consolidated with two courses of high-dose chemotherapy and stem cell support. The first course consisted of CVP, the second one of BEAM. If progression occurred at any time during the treatment, patients were removed from study. Because of this design, the length of treatment depended on the response observed. Patients received a minimum of two treatment cycles and a maximum of four. Treatment cycles were repeated at intervals of 4 weeks, when possible.
Ifosfamide/etoposide consisted of the following: prior to chemotherapy patients received sodium 2-mercaptoethanesulphate (mesna) 2 g/m 2 i.v. over 2 h. This was followed by ifosfamide 3. 
Supportive care
After every course of chemotherapy, patients received G-CSF 5 g/kg s.c. daily as described above. This dose was doubled to 5 g/kg twice a day after the course of ifosfamide/etoposide that was used for stem cell mobilization. After induction treatment with ifosfamide/etoposide and ifosfamide/mitoxantrone, patients received oral quinolones until recovery of neutrophil counts. After high-dose CVP or BEAM with stem cell rescue, patients received oral quinolones, fluconazole and acyclovir. Packed red blood cells were administered for hemoglobin Ͻ8 g/dl and platelets for a platelet count Ͻ20 × 10 9 /l. All blood products were filtered and irradiated. With BEAM chemotherapy, the patients received ice chips to prevent mucositis. 7 
Post-transplant evaluation and response criteria
Toxicity was assessed according to the criteria of Bearman et al. 8 Adverse events that could be attributed to infection (culture-documented), bleeding, or other medications were PD (6) PR (27) SD ( not scored as regimen-related toxicity. The maximum toxicity was the highest grade recorded in any individual organ system and the cumulative toxicity score was the sum of the highest grades recorded for all eight organ systems.
Response to therapy was evaluated after every treatment course, approximately 3 months, 6 months and 1 year after transplant, and annually thereafter. Evaluation consisted of physical examination, blood counts, chest X-ray, computed tomography of the chest, abdomen, and pelvis and bilateral marrow aspirates and biopsies. Gallium scanning, although routinely used, was not considered in the formal assessment of response. Additional tests such as immunophenotyping of the blood and bone marrow, lymph node aspiration or biopsy were performed when clinically indicated. Complete response (CR) was defined as the disappearance of all clinical and radiological evidence of active tumor. Partial response (PR) was defined as a 50% or greater decrease in the sum of the products of all measured lesions. Stable disease was defined as no change in the size of the measurable lesions, or a response that was less than a partial remission and no progression for a minimum of 8 weeks. There could be no appearance of new lesions for this category.
Comparison group: MINE-ESAP-BEAC (DM90-116)
Between 1990 and 1993, patients with recurrent intermediate-grade lymphoma or with transformation from more indolent histology were eligible for study DM 90-116. 6 Eligibility criteria for this study were identical to those of DM94-002 except that bone marrow involvement was an exclusion criteria. Staging work-up and response criteria were also similar.
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Patients were treated with two courses of MINE chemotherapy. After two cycles they underwent restaging. Patients with stable or responsive disease underwent bone marrow harvest followed by two cycles of chemotherapy with the ESHAP regimen.
2 Those who continued to respond then underwent consolidation with high-dose BEAC chemotherapy and autologous bone marrow transplantation. 6 The conditioning regimen for the transplant consisted of BEAC. Patients received carmustine 300 mg/m 2 i.v. over 1 h on day −7, etoposide 100 mg/m 2 i.v. over 6 h every 12 h on day −6, −5, −4, −3 (total eight doses), cytarabine 100 mg/m 2 i.v. over 30 min every 12 h on day −6, −5, −4, −3 (total eight doses) and cyclophosphamide 35 mg/kg i.v. over 1 h on day −6, −5, −4, −3 (total four doses). The bone marrow harvest was not purged in the majority of patients, but in four cases purging with a monoclonal anti-CD19 antibody and immunomagnetic beads was used. 9 Patients routinely received G-CSF 5 g/kg per day subcutaneously starting the day after marrow infusion and continuing until an ANC Ͼ500 was achieved. All patients were treated in private rooms and received prophylactic antibiotics and antifungal and antiviral prophylaxis. Irradiated blood products were administered to maintain Hb Ͼ8 g/dl and platelets Ͼ20 × 10 9 /l.
Statistical methods
Primary outcomes analyzed were progression-free and overall survival. Probabilities of primary outcomes were calculated using the Kaplan-Meier product-limit estimate, 10 and expressed as probabilities with a 95% confidence inter-val. Data from studies DM90-116 and DM94-002 were combined to examine the association of patient-, disease-, and treatment-related variables with survival. Univariate comparisons used the log-rank test (Table 1) . 11 Multivariate analysis used the Cox regression models. All potential risk factors were checked, with time-dependent covariates, to ensure that assumptions of proportionality were met. 12 Factors were then tested for their association with death by means of forward stepwise selection of variables. All comparisons reaching the 0.05 level of significance are presented, but because multiple comparisons were made, those with P values greater than 0.01 should be interpreted with caution. Because of significant interaction of factors, results regarding phenotype and disease stage were combined (Table 4) .
Results

Patient characteristics DM94-002
Forty four eligible patients were enrolled between March 1994 and September 1996. All 44 patients were evaluable. Median follow-up for surviving patients is 52 months (range 32 months to 62 months). Patient characteristics are summarized in Table 1 . Median age at study entry was 50 (range 24-61). Thirty six patients were treated at the time of first recurrence, eight had had a second recurrence prior to treatment on this protocol. Eleven patients had transformed lymphoma and seven patients had a T cell phenotype.
Response
Response rates are summarized in Table 2 (see also Figure 1 ). The response rate after one course of ifosfamide/etoposide was 77% (95% CI: 64-90) (34/44). The complete response rate was 16% (95% CI: 5-27) (7/44). Forty one patients went on to receive a second course which consisted of ifosfamide and mitoxantrone. In 37 cases, the second cycle was given to improve response in patients who had achieved PR (n = 27) or stable disease (n = 10). In four cases, patients who had achieved CR, received a second cycle for logistical reasons (ie awaiting insurance approval for transplantation). After completion of both cycles of induction treatment the response rate was 73% (95% CI: 61-85) (32/44). The complete response rate was 41% (95% CI: 27-55) (18/44). Thirty five patients (77% CI: 65-89) completed consolidation with high-dose chemotherapy. Seventeen patients underwent double consolidation with CVP followed by BEAM. Seventeen patients received BEAM alone, and one patient received a busulfan-based conditioning regimen (see below). One responding patient did not undergo transplantation as planned because he suffered a myocardial infarction prior to admission for high-dose chemotherapy. This event was likely unrelated to his treatment.
Treatment-related toxicity
Myelosuppression: Ifosfamide-etoposide and ifosfamidemitoxantrone with G-CSF support resulted in profound neutropenia. The median nadir granulocyte count was 0 after ifosfamide/etoposide (range 0-0.2) and after ifosfamide/mitoxantrone (range 0-0.8). The median duration of neutropenia (ANC Ͻ0.5 × 10 9 /l) was 6 days after ifosfamide/etoposide (range 4-10) and 5 days after ifosfamide/mitoxantrone (range 3-12). Information on transfusion requirements was available for 42 of 44 patients receiving ifosfamide/etoposide. Twenty four of these required platelet transfusions (median 1, range 0-2). Eighteen required blood transfusion (median 0, range 0-8). Similarly, information on transfusion requirements was available for 38 of 41 patients receiving ifosfamide/mitoxantrone. Twenty five of 38 required a Table 2 Response and outcomes DM94-002 (n = 44)
Response rate after one cycle (ifosfamide-etoposide) CR: 7 (16%) CR + PR: 34 (71%) Response rate after two cycles (ifosfamide-etoposide CR: 18 (41%) and ifosfamide-mitoxantrone) CR + PR: 32 (73%) Patients consolidated with transplantation 35 (77%) 2 year progression-free survival 38% ± 13% 2 year survival 52% ± 15% median of one platelet transfusion (range 0-4). Twenty seven required blood transfusions (median 2, range 0-6). Non-hematologic toxicities were mild. Grade II toxicity occurred in only one patient, who had a severe pain reaction to etoposide with each treatment cycle. Other toxicities included mild mucositis and alopecia. Ifosfamide-related encephalopathy occurred in one patient. Fatal or life-threatening toxicities did not occur. Toxicity of high-dose chemotherapy with stem cell transplantation was also limited to myelosuppression. The median time to recovery of ANC Ͼ0.5 was 9 days after CVP (range 7-12) and after BEAM (range 7-12). After CVP, the maximum observed toxicity was grade I. After BEAM, one case of grade II pulmonary toxicity occurred that was reversed with steroid treatment. The patient with a history of allergic reaction to etoposide was felt not to be likely to tolerate BEAM. Instead he received a thiotepa, busulfan and cyclophosphamide combination that has previously been used for the treatment of NHL. 13 He developed ARDS and died on day 17 after transplantation.
Survival and disease-free survival and recurrence rate
Twenty of the 44 patients remain alive and 14 are progression free. Progression-free survival at 2 years is 38% (95% CI: 24-52). Survival at 2 years is 52% (95% CI: 37-67). All but two treatment failures were due to disease progression (one treatment-related death after transplant and one death from adenocarcinoma of unknown primary). Disease progression occurred during induction treatment with ifosfamide in six patients. Three additional patients developed disease progression after CVP. In the remainder it occurred after autologous transplantation, usually within the first 6 months after completion of treatment. There were three recurrences more than 3 years after enrollment. Late progression presented as low-grade histology in one patient and with aggressive histology in two.
Prognostic factors (Table 4)
For the analysis of prognostic features relating to survival, the data on the 44 patients participating in DM94-002 were combined with those on 53 patients participating in DM90-116 (Mine-Eshap-BEAC), the characteristics of whom are detailed in Table 1 . Follow-up for surviving patients is 5.4 years (range 3.3-9.2 years). Thirty seven patients remain alive and twenty seven are free of disease. Survival at three years is 44% ± 10%, progression-free survival at 3 years is 33% ± 10% (Figure 2) . A multivariate analysis showed that an increased serum LDH (analyzed as a categorical variable: elevated vs normal) was significantly associated with worse survival (Figure 3) . Disease stage was an independent predictor for survival in patients with non-B cell lymphoma. Phenotype (B cell vs non-B cell) was an independent predictor for survival in patients with advanced disease stage. On the other hand, among patients with B cell NHL, no significant survival advantage was associated with lower disease stage. Similarly, B cell phenotype was not associated with an improved outcome among patients with low disease stage. Other disease-or patient-related variables, such as duration of first remission, age or extranodal disease, did not correlate with survival. Importantly, the salvage regimen used did not correlate with survival ( Figure 4) .
Discussion
Many groups have tested intensive ifosfamide-based salvage regimens for reinduction therapy of recurrent NHL. 
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Various doses and combinations of ifosfamide with other agents have been reported (Table 3) . We chose to evaluate a regimen of high-dose ifosfamide with etoposide, and alternated it with ifosfamide and mitoxantrone. The choice of these agents was based on their demonstrated activity in large cell NHL, the fact that they are not commonly used in front-line treatment and encouraging results from a previous pilot study. 14 The agents are similar to those used in the MINE regimen, 2 but represent a considerable dose escalation (Table 3) . We considered the achievement of complete remission an important intermediary end-point. We hypothesized that increased dose-intensity might increase the rate of partial and complete remissions, and ultimately result in improvement in long-term outcome after autologous transplantation. [15] [16] [17] [18] [19] With filgrastim and prophylactic antibiotics, we were able to administer this regimen at 4-week intervals. Myelosuppression was profound, but relatively short. With antibiotic prophylaxis and transfusion support, no life-threatening complications occurred. The nadir granulocyte count was much lower than that observed with the ESHAP or the MINE regimen, but no deaths due to neutropenic infection occurred with this regimen in contrast to five deaths out of 122 patients after ESHAP, 1 and two deaths out of 61 patients under the age of 60 treated with MINE-ESHAP. 2, 20 The limited duration of neutropenia and the use of prophylactic quinolones are probably responsible for the low incidence of severe infections. The response rate of 77% with this regimen was achieved within one or two cycles of treatment. In addition to the high response rates, this regimen was used for stem cell collection. As detailed in another publication, a median number of 13.1 × 10 6 CD34 positive (range 4.1-148) cells per kg were collected in a median of two phereses (range 1-10) during the recovery from the first cycle of chemotherapy. 21 This high mobilization efficiency may in part be due to the combination of an alkylating agent with etoposide as previously shown by Demirer et al 22 and is again similar to the data with ICE or other ifosfamide combinations (Table 3) . 19, 23, 24 Responding patients were consolidated with BEAM and autologous stem cell transplantation or with double consolidation with CVP and BEAM if they had achieved a partial remission, further increasing the intensity of this regimen. The entire treatment sequence consisting of salvage chemotherapy and autologous transplantation lasted a median of 111 days (range 68 to 167 days), which is considerably shorter than salvage regimens that are traditionally used. The median duration of treatment with the MINE-ESHAP-BEAC sequence, used in our previous study, 5 was 180 days (range 141-255, P Ͻ 0.01). With a median follow-up of 4. years, approximately 40% of all the patients continue to be progression-free.
Unfortunately, only a minority of patients achieved durable remissions, despite consolidation with autologous transplantation, and multivariate analysis indicated that there was no major survival benefit to the use of the more intensive high-dose ifosfamide-based regimens compared with MINE/ESHAP (Figure 3) . While the limited number of patients would allow only detection of major differences, overall survival was clearly affected more by the patient's disease status than by the type of salvage chemotherapy used. These data are reminiscent of the recent data of Moskowitz et al 19 where, despite an impressive response rate, durable survival was achieved in only 33% of patients. Unfortunately, in the setting of recurrent NHL, the impact of high-dose ifosfamide regimens on long-term outcome is limited when compared with more commonly used salvage regimens. Duration of response in recurrent NHL may be more dependent on patient characteristics than on the type of salvage administered. 1, 2, 4, 25, 26 Hence, it becomes important to be able to distinguish patients that will benefit from salvage therapy and autologous transplantation from those who will not obtain durable responses. Several groups have recently reported on prognostic features in patients with recurrent aggressive NHL. 4, [26] [27] [28] We confirmed that serum LDH provided strong independent prognostic information in patients with recurrent NHL. The association of disease stage with survival was less significant (P = 0.02) and there was a strong interaction of this parameter with phenotype (Table 4) . Patients with B cell phenotype had a better outcome than others, especially when patients with advanced disease were compared. As in other studies, B cell lymphoma constituted the majority of the patients, and the sample of non-B cell lymphomas was quite small and heterogeneous. 29, 30 Therefore, these data should be interpreted with caution. They are however consistent with recent reports that indicate a superior outcome for patients with B cell NHL. 29, 30 In conclusion, high-dose ifosfamide-based regimens with growth factor support induce high response rates, with limited toxicity, a shorter duration of treatment and with the ability to mobilize large numbers of stem cells, but they do not have a major impact on duration of remission in patients with recurrent aggressive NHL. 26 Serum LDH provides a reproducible parameter that allows the assessment of prognosis in patients with recurrent lymphoma who are Table 4 Adverse prognostic features for survival by multivariate analysis (data from DM90116 and DM94-002, n = 97)
Relative risk P value
LDH (elevated vs normal) 
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candidates for high-dose chemotherapy. Disease stage and disease phenotype provide additional prognostic information and could be used to further define the prognosis in patients with normal LDH. Only patients with favorable prognostic features such as low LDH and B cell phenotype should be entered on studies of salvage chemotherapy and autologous transplantation. Other patients should be offered participation in investigational treatments that may be more phenotype-specific or that exploit immune effects.
